Baas and colleagues retrospectively evaluated the predictive value for biochemical persistence (BCP) and early BCR of metastatic lymph node on PSMA PET/CT in 213 intermediate-risk and high-risk prostate cancer patients prior to radical treatment (RARP with ePLND). This evidence concerns the gene FOLH1 and prostate carcinoma.